Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors
暂无分享,去创建一个
Yrjö Collan | Pia Boström | Y. Collan | T. Vahlberg | P. Boström | M. Söderström | O. Carpén | P. Hirsimäki | Tero Vahlberg | Olli Carpen | Mirva Söderström | Tuire Palokangas | Pirkko Hirsimäki | Tuire Palokangas
[1] K. Jirström,et al. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. , 2005, Cancer research.
[2] M. Peters,et al. Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer. , 2004, Oncology reports.
[3] T. Hwang,et al. Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients , 2003, Pathology international.
[4] O. Barbash,et al. SCF(Fbx4/alphaB-crystallin) E3 ligase: when one is not enough. , 2008, Cell cycle.
[5] D. Germain,et al. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3. , 2008, Cancer research.
[6] H. Nevanlinna,et al. Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer , 2008, Breast Cancer Research and Treatment.
[7] O. Fadare,et al. Clinical and pathologic aspects of basal-like breast cancers , 2008, Nature Clinical Practice Oncology.
[8] H. Nevanlinna,et al. High cyclin B1 expression is associated with poor survival in breast cancer , 2009, British Journal of Cancer.
[9] L. Rydén,et al. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients , 2004, British Journal of Cancer.
[10] A. Hautamäki,et al. The national research and development centre for welfare and health. , 1993 .
[11] A. Thompson,et al. Cyclin D1 and breast cancer. , 2006, Breast.
[12] L. Skoog,et al. Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance , 2005, Breast Cancer Research and Treatment.
[13] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[14] Jeffrey E. Green,et al. Molecular Profiling in Breast Cancer , 2006 .
[15] Isabelle Bedrosian,et al. Cyclin E and survival in patients with breast cancer. , 2002, The New England journal of medicine.
[16] A. Bednarek,et al. Cyclin E expression in operable breast cancer quantified using real-time RT-PCR: a comparative study with immunostaining. , 2006, Japanese journal of clinical oncology.
[17] M. Fernö,et al. Expression of cyclins E, A, and B, and prognosis in lymph node‐negative breast cancer , 2003, The Journal of pathology.
[18] S. Inoue,et al. Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor , 2007, Cancer science.
[19] O. Topolcan,et al. The importance of prognostic factors in premenopausal women with breast cancer. , 2007, Anticancer research.
[20] H. Nevanlinna,et al. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut‐off values? , 2007, Histopathology.
[21] A. Tutt,et al. Triple negative tumours: a critical review , 2007, Histopathology.
[22] O. Barbash,et al. SCFFbx4/αB-crystallin E3 ligase: When one is not enough , 2008 .
[23] C. Blomqvist,et al. Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer , 2005, British Journal of Cancer.
[24] A. Bednarek,et al. Cyclin E expression in breast cancer correlates with negative steroid receptor status, HER2 expression, tumor grade and proliferation. , 2006, Journal of experimental & clinical cancer research : CR.